Stefanie Rodenbeck, MD
Neurology · Indianapolis, INNPI 1942654744
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,513 of the $19,366 with a category attached, or 69.8%. AstraZeneca accounts for 63.1% of it on its own, with 6 other manufacturers making up the rest.
Across 36 payments — averaging $537.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$12K
- Amgen$4K
- TG Therapeutics, Inc.$3K
- Novartis$143
- UCB, Inc.$139
- Sanofi$21
- plus $15 from 1 others
Across 10 payments — averaging $1773.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$11K
- Genentech, Inc.$7K
What the payments were for
- Consulting fees$13,51370%
- Speaking & faculty fees$3,54018%
- Travel & lodging$3352%
- Food & beverage$1,97910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $12,223 |
| Amgen | 11 | $4,057 |
| TG Therapeutics, Inc. | 4 | $2,766 |
| Novartis | 2 | $143 |
| UCB, Inc. | 1 | $139 |
| Sanofi | 1 | $21 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,366 in reported general payments places this provider in the 80th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TecfideraDimethyl Fumarate | 32 | $295,526 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 14 | $168,038 |
| Kesimpta PenOfatumumab | 17 | $159,160 |
| Avonex (4 Pack)Interferon Beta-1a | 19 | $153,379 |
| BetaseronInterferon Beta-1b | 11 | $105,434 |
| Glatiramer Acetate | 13 | $41,846 |
| Dalfampridine ErDalfampridine | 27 | $11,511 |
| FingolimodFingolimod Hcl | 11 | $6,328 |
| Teriflunomide | 12 | $5,466 |
| Modafinil | 18 | $1,542 |
| Gabapentin | 42 | $1,471 |
| AmantadineAmantadine Hcl | 11 | $956 |
| Pregabalin | 28 | $782 |
| Topiramate | 11 | $144 |
| Sodium Chloride0.9 % Sodium Chloride | 27 | $124 |
Paid to pharmacies, not to this prescriber.
Other neurology in Indianapolis
- Cassandra CurtisIndianapolis$181K
- Martin FarlowIndianapolis$148K
- Eric SiemersIndianapolis$101K
- Liana ApostolovaIndianapolis$95K
- Jared BroschIndianapolis$68K
- Kaustubh LimayeIndianapolis$44K
- Michael SermersheimIndianapolis$32K
- Cynthia McGarveyIndianapolis$27K
- David GlanderIndianapolis$25K
- Leo DambrosioIndianapolis$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.